Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Aktis Oncology Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Aktis Oncology Inc market cap is $1.09B.
What is the 52-week high for Aktis Oncology Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Aktis Oncology Inc 52 week high is $29.16 as of January 15, 2026.
What is the 52-week low for Aktis Oncology Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Aktis Oncology Inc 52 week low is $0.0372 as of January 15, 2026.
What is Aktis Oncology Inc stock price today?
Aktis Oncology Inc stock price today is $20.81.
What was Aktis Oncology Inc stock price yesterday?
Aktis Oncology Inc stock price yesterday was $21.35.
What is the Price-to-Book ratio of Aktis Oncology Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Aktis Oncology Inc P/B ratio is -12.4482.
What is the 50-day moving average of Aktis Oncology Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Aktis Oncology Inc 50-day moving average is $17.27.